

Table SII. 36-item Short-Form Health survey (SF-36) domains scores reported by patients with psoriasis treated with ixekizumab (IXE) or ustekinumab (UST) for 52 weeks

SF-36 domains	Week 4 Mean (SD)	Week 12 Mean (SD)	Week 24 Mean (SD)	Week 52 Mean (SD)
Bodily pain				
UST	12.24 (24.9)	14.55 (28.8)	14.21 (30.9)	15.32 (29.3)
IXE	19.73 (27.9)*	21.83 (29.7)*	23.10 (30.6)*	21.49 (30.4)*
General health				
UST	3.16 (15.4)	6.50 (17.5)	6.75 (17.5)	6.62 (19.4)
IXE	7.75 (16.5)*	8.88 (20.2)	11.62 (20.3)**	9.78 (18.9)
Mental health				
UST	4.66 (15.8)	5.67 (16.5)	6.50 (18.9)	7.42 (17.9)
IXE	6.78 (17.6)	8.41 (18.4)	7.86 (17.5)	7.81 (17.4)
Physical				
UST	3.45 (17.0)	5.15 (19.5)	6.06 (18.6)	5.64 (19.7)
IXE	6.67 (16.3)	10.63 (19.9)	9.59 (19.0)	9.59 (20.0)
Role emotional				
UST	3.69 (22.8)	4.09 (23.3)	2.98 (27.7)	5.05 (26.4)
IXE	5.00 (22.8)	5.93 (23.1)	5.41 (22.2)	4.57 (25.1)
Role physical				
UST	5.80 (21.9)	4.70 (23.8)	6.93 (23.2)	7.12 (26.1)
IXE	7.87 (24.4)	9.95 (25.6)	10.31 (27.6)	8.47 (26.1)
Social				
UST	5.98 (23.0)	9.92 (24.3)	12.05 (26.3)	12.58 (26.9)
IXE	10.07 (24.1)	9.17 (25.7)	13.06 (26.6)	11.94 (27.8)
Vitality				
UST	3.86 (16.0)	5.80 (18.2)	8.83 (19.4)	8.19 (19.7)
IXE	7.41 (20.3)	7.60 (21.9)	9.30 (21.6)	9.17 (22.2)

* $p < 0.05$ and ** $p < 0.01$, both vs UST by Wilcoxon rank sum test.